186 related articles for article (PubMed ID: 35781768)
21. An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.
Lalloo F; Cochrane S; Bulman B; Varley J; Elles R; Howell A; Evans DG
J Med Genet; 1998 Jan; 35(1):10-2. PubMed ID: 9475087
[TBL] [Abstract][Full Text] [Related]
22. Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel.
Rennert G; Dishon S; Rennert HS; Fares F
Eur J Cancer Prev; 2005 Aug; 14(4):357-61. PubMed ID: 16030426
[TBL] [Abstract][Full Text] [Related]
23. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
Lavie O; Narod S; Lejbkowicz F; Dishon S; Goldberg Y; Gemer O; Rennert G
Ann Oncol; 2011 Apr; 22(4):964-966. PubMed ID: 20924075
[TBL] [Abstract][Full Text] [Related]
24. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
Hodgson SV; Heap E; Cameron J; Ellis D; Mathew CG; Eeles RA; Solomon E; Lewis CM
J Med Genet; 1999 May; 36(5):369-73. PubMed ID: 10353781
[TBL] [Abstract][Full Text] [Related]
26. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
27. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
[TBL] [Abstract][Full Text] [Related]
28. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
[TBL] [Abstract][Full Text] [Related]
29. Hereditary breast/ovarian cancer--pitfalls in genetic counseling.
Dagan E; Gershoni-Baruch R
Clin Genet; 2001 Oct; 60(4):310-3. PubMed ID: 11683778
[TBL] [Abstract][Full Text] [Related]
30. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
Robson M; Dabney MK; Rosenthal G; Ludwig S; Seltzer MH; Gilewski T; Haas B; Osborne M; Norton L; Gilbert F; Offit K
Genet Test; 1997; 1(1):47-51. PubMed ID: 10464625
[TBL] [Abstract][Full Text] [Related]
32. Current detection rates and time-to-detection of all identifiable
Manchanda R; Blyuss O; Gaba F; Gordeev VS; Jacobs C; Burnell M; Gan C; Taylor R; Turnbull C; Legood R; Zaikin A; Antoniou AC; Menon U; Jacobs I
J Med Genet; 2018 Aug; 55(8):538-545. PubMed ID: 29622727
[TBL] [Abstract][Full Text] [Related]
33. BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening.
Shkedi-Rafid S; Gabai-Kapara E; Grinshpun-Cohen J; Levy-Lahad E
Genet Med; 2012 Jul; 14(7):688-94. PubMed ID: 22481128
[TBL] [Abstract][Full Text] [Related]
34. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
[TBL] [Abstract][Full Text] [Related]
35. Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing.
Francke U; Dijamco C; Kiefer AK; Eriksson N; Moiseff B; Tung JY; Mountain JL
PeerJ; 2013; 1():e8. PubMed ID: 23638402
[TBL] [Abstract][Full Text] [Related]
36. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
Metcalfe KA; Poll A; Llacuachaqui M; Nanda S; Tulman A; Mian N; Sun P; Narod SA
Clin Genet; 2010 Nov; 78(5):411-7. PubMed ID: 20653694
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of two population screening programmes for
Cousens NE; Tiller J; Meiser B; Barlow-Stewart K; Rowley S; Ko YA; Mahale S; Campbell IG; Kaur R; Bankier A; Burnett L; Jacobs C; James PA; Trainer A; Neil S; Delatycki MB; Andrews L
BMJ Open; 2021 Jun; 11(6):e041186. PubMed ID: 34172541
[TBL] [Abstract][Full Text] [Related]
38. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
Hartge P; Struewing JP; Wacholder S; Brody LC; Tucker MA
Am J Hum Genet; 1999 Apr; 64(4):963-70. PubMed ID: 10090881
[TBL] [Abstract][Full Text] [Related]
39. A family with three germline mutations in BRCA1 and BRCA2.
Liede A; Metcalfe K; Offit K; Brown K; Miller S; Narod SA; Moslehi R
Clin Genet; 1998 Sep; 54(3):215-8. PubMed ID: 9788724
[TBL] [Abstract][Full Text] [Related]
40. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing JP; Hartge P; Wacholder S; Baker SM; Berlin M; McAdams M; Timmerman MM; Brody LC; Tucker MA
N Engl J Med; 1997 May; 336(20):1401-8. PubMed ID: 9145676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
